Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications

Human Gene Therapy

Volumn 21, Issue 9, 2010, Pages 1155-1167

  Espenlaub, Sigrid ^a   Corjon, Stéphanie ^a,b   Engler, Tatjana ^a   Fella, Carolin ^c   Ogris, Manfred ^c   Wagner, Ernst ^c   Kochanek, Stefan ^a   Kreppel, Florian ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSOMER; DISULFIDE; FLUORESCENT DYE; HYDRAZONE DERIVATIVE; POLYMER; PROTEIN; PROTEIN IX; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL FATE; CHEMICAL BOND; CONTROLLED STUDY; DISULFIDE BOND; DNA MODIFICATION; FEMALE; HUMAN; HUMAN CELL; HYDRAZONE BOND; HYDROLYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PH; SIGNAL TRANSDUCTION; VIRION; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL TRANSPORT; CAPSID; CELL LINE; FLOW CYTOMETRY; FLUORESCENT DYES; GENETIC VECTORS; HUMANS; INTRACELLULAR SPACE; LIGANDS; MICROSCOPY, CONFOCAL; STAINING AND LABELING; VIRION;

ADENOVIRIDAE; COXSACKIEVIRUS; MIRIDAE;

EID: 77957832543     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.171     Document Type: Article

References (29)

1. Campos, S.K., and Barry, M.A. (2006). Comparison of adenovi-rus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 349, 453-462.
2. Corjon, S., Wortmann, A., Engler, T., Van Rooijen, N., Kochanek, S., and Kreppel, F. (2008). Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX cap-somere. Mol. Ther. 16, 1813-1824.
3. Croyle, M.A., Yu, Q.C., and Wilson, J.M. (2000). Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11, 1713-1722.
4. Fella, C., Walker, G.F., Ogris, M., and Wagner, E. (2008). Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding. Eur. J. Pharm. Sci. 34, 309-320.
5. Fisher, K.D., Stallwood, Y., Green, N.K., Ulbrich, K., Mautner, V., and Seymour, L.W. (2001). Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341-348.
6. Greber, U.F., Willetts, M., Webster, P., and Helenius, A. (1993). Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75, 477-486.
7. Green, N.K., Herbert, C.W., Hale, S.J., Hale, A.B., Mautner, V., Harkins, R., Hermiston, T., Ulbrich, K., Fisher, K.D., and Seymour, L.W. (2004). Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11, 1256-1263.
8. Kreppel, F., and Kochanek, S. (2008). Modification of adenovirus gene transfer vectors with synthetic polymers: A scientific review and technical guide. Mol. Ther. 16, 16-29.
9. Kreppel, F., Biermann, V., Kochanek, S., and Schiedner, G. (2002). A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum. Gene Ther. 13, 1151-1156.
10. Kreppel, F., Gackowski, J., Schmidt, E., and Kochanek, S. (2005). Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol. Ther. 12, 107-117.
11. Le, L.P., Everts, M., Dmitriev, I.P., Davydova, J.G., Yamamoto, M., and Curiel, D.T. (2004). Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol. Imaging 3, 105-116.
12. Lee, D., Walsh, J.D., Mikhailenko, I., Yu, P., Migliorini, M., Wu, Y., Krueger, S., Curtis, J.E., Harris, B., Lockett, S., Blacklow, S.C., Strickland, D.K., and Wang, Y.X. (2006). RAP uses a histidine switch to regulate its interaction with LRP in the ER and Golgi. Mol. Cell 22, 423-430.
13. Leopold, P.L., Ferris, B., Grinberg, I., Worgall, S., Hackett, N.R., and Crystal, R.G. (1998). Fluorescent virions: Dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Hum. Gene Ther. 9, 367-378.
14. Leopold, P.L., Kreitzer, G., Miyazawa, N., Rempel, S., Pfister, K.K., Rodriguez-Boulan, E., and Crystal, R.G. (2000). Dynein-and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Hum. Gene Ther. 11, 151-165.
15. Martin-Fernandez, M., Longshaw, S.V., Kirby, I., Santis, G., Tobin, M.J., Clarke, D.T., and Jones, G.R. (2004). Adenovirus type-5 entry and disassembly followed in living cells by
16. Meier, O., and Greber, U.F. (2003). Adenovirus endocytosis. J. Gene Med. 5, 451-462.
17. Meier, O., and Greber, U.F. (2004). Adenovirus endocytosis. J. Gene Med. 6(Suppl. 1), S152-S163.
18. Mok, H., Palmer, D.J., Ng, P., and Barry, M.A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11, 66-79.
19. Nakano, M.Y., Boucke, K., Suomalainen, M., Stidwill, R.P., and Greber, U.F. (2000). The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endo-cytosis and escape to the cytosol. J. Virol. 74, 7085-7095.
20. O'Riordan, C.R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S.C., Smith, A.E., and Francis, G.E. (1999). PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10, 1349-1358.
21. Rosa-Calatrava, M., Grave, L., Puvion-Dutilleul, F., Chatton, B., and Kedinger, C. (2001). Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J. Virol. 75, 7131-7141.
22. Saito, G., Swanson, J.A., and Lee, K.D. (2003). Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55, 199-215.
23. Schiedner, G., Hertel, S., and Kochanek, S. (2000). Efficient transformation of primary human amniocytes by E1 functions of Ad5: Generation of new cell lines for adenoviral vector production. Hum. Gene Ther. 11, 2105-2116.
24. Shayakhmetov, D.M., Li, Z.Y., Ternovoi, V., Gaggar, A., Ghar-wan, H., and Lieber, A. (2003). The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses. J. Virol. 77, 3712-3723.
25. Waehler, R., Russell, S.J., and Curiel, D.T. (2007). Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573-587.
26. Walker, G.F., Fella, C., Pelisek, J., Fahrmeir, J., Boeckle, S., Ogris, M., and Wagner, E. (2005). Toward synthetic viruses: Endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol. Ther. 11, 418-425.
27. Weaver, E.A., and Barry, M.A. (2008). Effects of shielding ade-noviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 19, 1369-1382.
28. Wolff, J.A., and Rozema, D.B. (2008). Breaking the bonds: Non-viral vectors become chemically dynamic. Mol. Ther. 16, 8-15.
29. Wortmann, A., Vohringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., Kochanek, S., and Kreppel, F. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154-162.